Ownership and insider activity for Amgen Inc. (AMGN): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience.
Price
| Price | $466.01 (closing price, October 30, 2026) |
| Market Cap | $251.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-10-26 | Gibbs David W | |||
| 2026-09-01 | Dittrich Thomas J.W. | |||
| 2027-08-07 | Dittrich Thomas J.W. | 17,201 | $7.1M | |
| 2026-08-13 | Khosla Rachna | M-Exempt | 1,252 | $204K |
| 2026-08-13 | Khosla Rachna | S-Sale | 1,252 | $521K |
| 2026-08-11 | Khosla Rachna | S-Sale | 2,000 | $825K |
| 2026-08-13 | Khosla Rachna | M-Exempt | 1,252 | $204K |
| 2026-08-07 | Busch Matthew C. | A-Award | 730 | |
| 2026-08-07 | ISHRAK OMAR | A-Award | 85 | |
| 2026-08-07 | HOLLEY CHARLES M | A-Award | 103 |
Balance Sheet (10y)
| Year | 2001 | 2002 | 2003 | 2004 | 2005 | 2006 | 2007 | 2008 | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $689.1M | $1.85B | $837.0M | $1.53B | $1.84B | $1.28B | $2.02B | $1.77B | $2.88B | $3.29B | $6.95B | $3.26B | $3.81B | $3.73B | $4.14B | $3.24B | $3.80B | $6.95B | $6.04B | $6.27B | $7.99B | $7.63B | $10.94B | $11.97B | $9.13B |
| Short-term Investments | $1.97B | $2.81B | $4.29B | $4.28B | $3.42B | $4.99B | $5.13B | $7.78B | $10.56B | $14.13B | $13.70B | $20.80B | $15.60B | $23.30B | $27.24B | $34.84B | $37.88B | $22.36B | $2.87B | $4.38B | $48.0M | $1.68B | 0 | 0 | 0 |
| Receivables | $497.2M | $752.0M | $1.01B | $1.46B | $1.77B | $2.12B | $2.10B | $2.07B | $2.11B | $2.33B | $2.90B | $2.52B | $2.70B | $2.55B | $3.00B | $3.17B | $3.24B | $3.58B | $4.06B | $4.53B | $5.84B | $6.39B | $7.94B | $7.50B | $9.57B |
| Inventory | $355.6M | $545.0M | $713.0M | $888.0M | $1.26B | $1.90B | $2.09B | $2.08B | $2.22B | $2.02B | $2.48B | $2.74B | $3.02B | $2.65B | $2.44B | $2.75B | $2.83B | $2.94B | $3.58B | $3.89B | $4.09B | $4.93B | $9.52B | $7.00B | $6.22B |
| Total Current Assets | $3.86B | $6.40B | $7.40B | $9.17B | $9.23B | $11.71B | $13.04B | $15.22B | $18.93B | $23.13B | $27.59B | $31.21B | $27.37B | $34.71B | $38.52B | $46.01B | $49.48B | $37.62B | $18.44B | $21.14B | $19.39B | $22.19B | $30.33B | $29.03B | $29.06B |
| Property, Plant & Equipment | $1.95B | $2.81B | $3.80B | $4.71B | $5.04B | $5.92B | $5.94B | $5.88B | $5.74B | $5.52B | $5.42B | $5.33B | $5.35B | $5.22B | $4.91B | $4.96B | $4.99B | $4.96B | $4.93B | $4.89B | $5.18B | $5.43B | $5.94B | $6.54B | $8.52B |
| Goodwill | 0 | 0 | 0 | 0 | 0 | $11.30B | $11.24B | $11.34B | $11.34B | $11.33B | $11.75B | $12.66B | $14.97B | $14.79B | $14.79B | $14.75B | $14.76B | $14.70B | $14.70B | $14.69B | $14.89B | $15.53B | $18.63B | $18.64B | $18.68B |
| Intangible Assets | 0 | $14.67B | $14.11B | $14.56B | $14.24B | $3.75B | $3.33B | $2.99B | $7.87B | $2.23B | $2.58B | $3.97B | $13.26B | $12.69B | $11.64B | $10.28B | $8.61B | $7.44B | $19.41B | $16.59B | $15.18B | $16.08B | $32.64B | $27.70B | $22.28B |
| Total Assets | $6.44B | $24.46B | $26.18B | $29.22B | $29.30B | $33.79B | $34.64B | $36.44B | $39.63B | $43.49B | $48.87B | $54.30B | $66.12B | $69.01B | $71.58B | $77.63B | $79.95B | $66.42B | $59.71B | $62.95B | $61.16B | $65.12B | $97.15B | $91.84B | $90.59B |
| Accounts Payable | $136.7M | $255.0M | $327.0M | $507.0M | $596.0M | $555.0M | $378.0M | $504.0M | $574.0M | $716.0M | $642.0M | $905.0M | $787.0M | $995.0M | $965.0M | $917.0M | $1.35B | $1.21B | $1.37B | $1.42B | $1.37B | $1.57B | $1.59B | $1.91B | $2.37B |
| Short-term Debt | $99.9M | $123.0M | 0 | $1.17B | 0 | $1.88B | $2.00B | $1.00B | 0 | $2.49B | $84.0M | $2.50B | $2.50B | $500.0M | $2.25B | $4.40B | $1.15B | $4.42B | $2.95B | $91.0M | $87.0M | $1.59B | $1.44B | $3.55B | $4.60B |
| Total Current Liabilities | $1.00B | $1.53B | $2.46B | $4.16B | $3.60B | $7.02B | $6.18B | $4.89B | $3.87B | $6.57B | $5.75B | $8.19B | $7.95B | $7.01B | $8.66B | $11.20B | $9.02B | $13.49B | $12.84B | $11.65B | $12.18B | $15.69B | $18.39B | $23.10B | $25.49B |
| Long-term Debt | $223.0M | $3.05B | $3.08B | $3.94B | $3.96B | $7.13B | $9.18B | $9.18B | $10.60B | $10.87B | $21.34B | $24.03B | $29.62B | $30.21B | $29.18B | $30.19B | $34.19B | $29.51B | $26.95B | $32.90B | $33.22B | $37.35B | $63.17B | $56.55B | $50.01B |
| Total Liabilities | $1.23B | $6.17B | $6.72B | $9.52B | $8.85B | $14.82B | $16.77B | $16.06B | $16.96B | $19.54B | $29.84B | $35.24B | $44.03B | $43.23B | $43.37B | $47.75B | $54.71B | $53.92B | $50.03B | $53.54B | $54.47B | $61.46B | $90.92B | $85.96B | $81.93B |
| Retained Earnings | $1.69B | -$1.13B | -$667.0M | -$2.38B | -$3.13B | -$5.20B | -$7.16B | -$5.26B | -$4.32B | -$3.51B | -$8.92B | -$10.42B | -$7.63B | -$4.62B | -$2.09B | -$438.0M | -$5.07B | -$17.98B | -$21.33B | -$21.41B | -$24.60B | -$28.62B | -$26.55B | -$27.59B | -$25.11B |
| Total Equity | $5.22B | $18.29B | $19.39B | $19.70B | $20.45B | $18.96B | $17.87B | $20.39B | $22.67B | $23.94B | $19.03B | $19.06B | $22.10B | $25.78B | $28.08B | $29.88B | $25.24B | $12.50B | $9.67B | $9.41B | $6.70B | $3.66B | $6.23B | $5.88B | $8.66B |
| Total Debt | $322.9M | $3.17B | $3.08B | $5.11B | $3.96B | $9.01B | $11.18B | $10.18B | $10.60B | $13.36B | $21.43B | $26.53B | $32.13B | $30.71B | $31.43B | $34.60B | $35.34B | $33.93B | $29.90B | $32.99B | $33.31B | $38.95B | $64.61B | $60.10B | $54.60B |
| Net Debt | -$2.34B | -$1.49B | -$2.04B | -$698.0M | -$1.30B | $2.73B | $4.03B | $624.0M | -$2.84B | -$4.06B | $787.0M | $2.47B | $12.73B | $3.69B | $47.0M | -$3.49B | -$6.34B | $4.62B | $20.99B | $22.34B | $25.27B | $29.64B | $53.67B | $48.13B | $45.48B |
| Working Capital | $2.86B | $4.88B | $4.95B | $5.01B | $5.64B | $4.69B | $6.86B | $10.34B | $15.06B | $16.56B | $21.84B | $23.02B | $19.42B | $27.70B | $29.85B | $34.81B | $40.46B | $24.13B | $5.61B | $9.49B | $7.20B | $6.50B | $11.94B | $5.93B | $3.57B |
Financial Health
| Debt / Equity | 4.90 |
| Current Ratio | 1.37 |
| Piotroski F-Score | 8 |
| Altman Z-Score | 1.74 |
Profitability
| Return on Equity | 89.32% |
| Return on Invested Capital | 14.22% |
| Return on Assets | 9.14% |
| Gross Margin | 72.65% |
| Operating Margin | 33.18% |
| Net Margin | 22.93% |
Related companies: MRK · LLY · JNJ · ABBV · AZN · NVS · PFE · BMY
Explore sector: Healthcare · Drug Manufacturers - General
More sections of AMGN: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method today · Companies that pass the Lynch method today · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks